RxDoctor Payments Data

Shawn Nelson, MD

Neurology · Bristol, TNNPI 1346233020

Payments from drug & device makers

$19,677in general payments, 2019–2025

Across 1,027 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Novartis$1K
  • Lilly USA, LLC$969
  • Neurelis, Inc.$935
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$230%
  • Food & beverage$19,646100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.83$2,288
AbbVie(2 entities)143$1,943
AstraZeneca(2 entities)55$1,243
Novartis57$1,031
Lilly USA, LLC55$969
Neurelis, Inc.27$935
Lundbeck LLC48$909
Biogen43$774
MDD US Operations, LLC34$608
Acadia Pharmaceuticals Inc40$576
Genentech USA, Inc.27$526
Eisai Inc.26$504
Teva Pharmaceuticals USA, Inc.31$422
TG Therapeutics, Inc.11$384
Pfizer27$377
Amgen(2 entities)18$377
Argenx US, Inc.18$346
Bristol Myers Squibb18$346
Kyowa Kirin, Inc.15$313
Neurocrine Biosciences, Inc.18$307
Jazz Pharmaceuticals Inc.10$303
Sanofi12$275
SK Life Science, Inc.11$272
Sunovion Pharmaceuticals Inc.19$263
Upsher-smith Laboratories LLC14$236
Avanir Pharmaceuticals, Inc.11$185
Supernus Pharmaceuticals, Inc.9$184
Amneal Pharmaceuticals LLC10$179
Impel Pharmaceuticals Inc.7$165
CSL Behring7$160
Adamas Pharmaceuticals, Inc.7$147
Mallinckrodt Hospital Products Inc.6$136
Merz Pharmaceuticals, LLC6$134
Sumitomo Pharma America, Inc.8$134
Otsuka America Pharmaceutical, Inc.6$128
Johnson & Johnson8$126
Ipsen Biopharmaceuticals, Inc6$124
Biohaven Pharmaceuticals, Inc.8$122
Biohaven Pharmaceutical Holding Company Ltd.6$117
Aprecia Pharmaceuticals, LLC5$82
Corium, LLC4$80
Greenwich Biosciences, Inc.3$75
Takeda Pharmaceuticals U.S.A., Inc.5$67
EMD Serono, Inc.4$64
Catalyst Pharmaceuticals, Inc.3$63
Avion Pharmaceuticals3$61
E.r. Squibb & Sons, L.L.C.4$60
Arbor Pharmaceuticals, Inc.4$57
Mallinckrodt Enterprises LLC3$54
Aucta Pharmaceuticals, Inc.2$51
Harmony Biosciences LLC2$42
Assertio Therapeutics, Inc.3$41
Scilex Pharmaceuticals Inc.2$38
Akcea Therapeutics, Inc.2$34
GE HealthCare1$27
Livanova USA, Inc.2$26
Vanda Pharmaceuticals Inc.1$25
Impel Pharmaceuticals LLC1$23
Banner Life Sciences, LLC1$20
Grifols USA, LLC1$20

How this compares

$19,677 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$60,496
Medicare patients
333
Services billed
723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5014$393,501
VumerityDiroximel Fumarate21$182,254
Avonex (4 Pack)Interferon Beta-1a13$108,003
Avonex Pen (4 Pack)Interferon Beta-1a14$106,818
BotoxOnabotulinumtoxina56$82,026
QuliptaAtogepant62$79,309
Nurtec OdtRimegepant Sulfate51$74,672
Emgality PenGalcanezumab-Gnlm50$45,611
AptiomEslicarbazepine Acetate13$30,240
Emgality SyringeGalcanezumab-Gnlm26$21,812
VimpatLacosamide24$21,127
Topiramate ErTopiramate17$18,432
Keppra XrLevetiracetam12$17,981
Aimovig AutoinjectorErenumab-Aooe17$14,634
ValtocoDiazepam15$11,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$160$393,50114 claims
BiogenVumerity, Avonex (4 Pack)$774$290,25734 claims
AbbVieBotox, Qulipta, Ubrelvy$1,943$173,130130 claims
PfizerNurtec Odt$377$74,67251 claims
Sunovion Pharmaceuticals Inc.Aptiom$263$30,24013 claims
UCB, Inc.Vimpat$2,288$21,12724 claims
Neurelis, Inc.Valtoco$935$11,94015 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$179$3,27848 claims
Upsher-smith Laboratories LLCTopiramate$236$2,627271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.

Other neurology in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →